Pimavanserin is an atypical antipsychotic used to manage Parkinson’s disease psychosis. It acts as a 5-HT2A receptor inverse agonist and antagonist. Unlike other antipsychotics, pimavanserin does not interact with D2 receptors, making it ideal for treating psychosis symptoms while preserving motor function.